Skip to main content
ANVS
NYSE Life Sciences

Director Hoffman Buys $5M of Annovis Offering — 5M Shares Plus 5M Warrants at $1.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.88
Mkt Cap
$36.06M
52W Low
$0.616
52W High
$5.5
52W Position info
43% above low
Off High info
84% below high
Rel. Volume info
5.7× avg
Market data snapshot near publication time

ANVS sits 43% above its 52-week low of $0.616 on elevated volume (5.7× avg).

Summary

Director Michael B. Hoffman bought 5,000,000 shares and 5,000,000 warrants at a combined $1.00 per unit, $5 million total, in Annovis's just-priced offering. His direct stake rose to 8,364,883 shares.


Key Events · Ownership and Investor Activity · ANVS

  • Director Buys $5M in Offering

    Michael B. Hoffman acquired 5,000,000 shares and 5,000,000 warrants for a combined $1.00 per unit, $5,000,000 total, on 2026-11-06.

  • Stake Rises to 8.36M Shares

    Post-transaction direct holdings are 8,364,883 shares, plus 223,357 shares held indirectly through the 2024 Hoffman Family Trust.

  • Warrants Strike at $1.00

    The 5,000,000 warrants carry a $1.00 exercise price and expire 2031-11-06, so they pay off only above the offering price.

  • Follows Offering and Share Authorization

    Comes one day after the $21.0M offering priced on 2026-11-05 and the same week stockholders approved doubling authorized shares to 140 million on 2026-11-04.


Analysis · ANVS · Life Sciences

A board member put $5 million of his own money into the offering Annovis priced on November 5, taking 5,000,000 shares and 5,000,000 warrants at a combined $1.00 per unit. That is real cash, not an option exercise, and it is large next to a company with a roughly $36 million market value. The purchase also lands the day after stockholders approved doubling authorized shares to 140 million, so the raise it funds is the same capital that keeps a going-concern-flagged balance sheet alive. The warrants carry a $1.00 strike and expire in 2031, so his economics improve only if the stock climbs above the offering price.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANVS was trading at $0.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.1M. The 52-week trading range was $0.62 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.8799 info
Change: +$0.011 (+1%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.8799 info
Change: -$0.0601 (-6%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8507
Real-time Price: $0.8799 info
Change: +$0.0292 (+3%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.880
Real-time Price: $0.8799 info
Change: -$0.0001 (-0.01%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.8799 info
Change: -$0.3301 (-27%) info
Market Cap: $36.06M info